Catheter Precision Inc. (NYSEAMERICAN: VTAK), based in the United States that specializes in developing innovative solutions for the treatment of cardiac arrhythmias. They collaborate with physicians to create cutting-edge technology for electrophysiology procedures. One of their notable products is the VIVO™ (View into Ventricular Onset) 3D mapping system.

The VIVO™ 3D mapping system is designed to provide a cost-effective solution for improving the treatment of cardiac arrhythmias. It aims to reduce procedure costs and enhance patient outcomes while making a significant impact on the industry. The system is known for its high accuracy, with a reported 99.5% precision in detecting ventricular dysrhythmias, which are critical for effective treatment. Additionally, the implementation of VIVO™ has been shown to substantially reduce procedure times, with reductions ranging from 75% to 84% in the electrophysiology lab.

A significant development for Catheter Precision Inc. occurred on October 12 when the company announced that its VIVO™ 3D mapping system had received national reimbursement in the United Kingdom. This was achieved through its inclusion in the High-Cost Tariff Excluded Devices (HCTED) system, which is operated by the National Health Service England (NHS England). This inclusion allows hospitals to directly bill the cost of single-use products to the NHS. This recognition is expected to facilitate the broader adoption of VIVO™ technology in the UK and improve market access for the product.

In addition to its success in the UK, Catheter Precision Inc. expanded its reach by entering into a distribution partnership with Somnotec (S) Pte Ltd., a medical device distributor based in Singapore. Through this partnership, Somnotec is responsible for distributing Catheter Precision’s LockeT closure device in several Asian countries, including Malaysia, Singapore, Brunei, Indonesia, and the Philippines.

Overall, Catheter Precision Inc. appears to be actively working to improve the treatment of cardiac arrhythmias through innovative medical devices and strategic partnerships, with a focus on both technological advancement and expanding its market presence.